Brief: Rani Therapeutics Unit And Celltrion Entered Into A License And Supply Agreement
05/06/2023 16:19
June 5 (Reuters) - Rani Therapeutics Holdings Inc
RANI.O :
* RANI THERAPEUTICS HOLDINGS INC - ON JUNE1, UNIT AND
CELLTRION,
INC. ENTERED INTO A LICENSE AND SUPPLY AGREEMENT
* RANI THERAPEUTICS : CELLTRION WILL PROVIDE, AND RANI WILL
PURCHASE, SUPPLY OF ADALIMUMAB BIOSIMILAR AT SUPPLY PRICES SET
FORTH IN LICENSE DEAL
Source text for Eikon: ID:
Further company coverage: RANI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rani Therapeutics Holdings
See all newsRani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Brief: Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Pegbio Co Enters MoU With Rani Therapeutics
Brief: Rani Therapeutics Announces R&D Collaboration With PegBio
Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition